The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats (Q42551979)

2 November 2017

title

The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats (English)

1 reference

2 November 2017

McAllister KH

1

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 October 1996

1 reference

European Journal of Pharmacology

2 November 2017

published in

1 reference

2 November 2017

volume

314

1 reference

2 November 2017

issue

3

1 reference

2 November 2017

page(s)

307-311

1 reference

Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

The pharmacology of SDZ EAA 494, a competitive NMDA antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Anticataleptic potencies of glutamate-antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2896%2900576-6

10.1016/S0014-2999(96)00576-6

7 January 2021

Identifiers

DOI

1 reference

2 November 2017

1 reference